Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The benefit of this diagnostic radiopharmaceutical is its potential to diagnose prostate cancer during primary staging of patients at high risk and in the staging of patients with a suspected recurrence
Findings from the prespecified final overall survival analysis of the PAOLA-1/ENGOT-ov25 study
Evidence for efficacy is based on the results from the EPCORE NHL-1 study
Findings from the MAINTAIN study
Findings from the CATCH-IT Consortium study
Before starting treatment with pralsetinib, patients should be evaluated for active and latent tuberculosis
PRO data from the DESTINY-Breast03 study
Findings from the ctDNA analysis in the VOYAGER study
Findings from the GAIA–CLL13 study
Findings from the COSMIC-313 study
It is intended for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic treatment
An inherited cancer-predisposition mechanism distinct from that of mutations affecting tumour-suppressor proteins and oncoproteins
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
